Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

our and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
(Date:8/21/2014)... August 21, 2014 SoundConnect ... been recognized as one of the nation’s Fastest ... magazine for the 2nd consecutive year. Inc. magazine ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that ... accepted for payment all shares validly tendered and not ... shares of common stock of Memory Pharmaceuticals Corp. (Nasdaq: ... cash.As of the expiration of the tender offer, a ...
... Inc.,(Nasdaq: BNVI ) announced today results ... to identify estrogenic drugs that are,safer. The data, ... new regulatory elements can distinguish the estrogenic,pharmacological activity ... prediction of specific tissue effect. , ...
... CHICAGO, Dec. 31 A landmark study published today ... that use of a specially-designed machine to store kidneys ... function when compared to those stored in a traditional ... the LifePort(R) Kidney Transporter monitors the temperature and vascular ...
Cached Biology Technology:Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 2Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 3Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp. 4Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 2Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 3Study Shows Machine Perfusion Significantly Improves Transplant Results 2Study Shows Machine Perfusion Significantly Improves Transplant Results 3
(Date:8/21/2014)... published in the journal Carcinogenesis by researchers ... for the protein adenomatous polyposis coli (APC) in suppressing ... in the U.S. , Lead author Kristi Neufeld, associate ... of the Cancer Biology program at the KU Cancer ... trying to understand the various activities of APC, a ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
(Date:8/20/2014)... 2014 /CNW/ -  Issue Serious allergic ... become life threatening for some children.    What ... Canadians have food allergies and this number may be increasing, ... are estimated to have food allergies.  The ... and hives to breathing difficulties and loss of consciousness. Symptoms ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Insulin offers new hope for the treatment of acute pancreatitis 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... in six will get prostate cancer during his lifetime, making ... a new partnership with Areva Med, UC researchers will investigate ... of prostate cancer tumors. In the study, UC researchers ... efficacy of a new agent targeted against a specific protein ...
... researchers from the Johns Hopkins University School of Medicine ... by European scientific institutions. Andrew P. Feinberg, M.D., ... of the Center for Epigenetics, will receive the honorary ... ceremony in the Stockholm City Hall on May 7. ...
... Researchers in China are reporting that they have found a ... cells -- that have been reprogrammed into a primordial, embryonic-like ... a paper published online last week by the Journal ... the Chinese Academy of Sciences point to a marker they ...
Cached Biology News:UC to test targeted treatment for prostate cancer 22 Hopkins scientists awarded European honorary doctorates 2Chinese scientists discover marker indicating the developmental potential of stem cells 2
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
...
... long and outstanding history in the ... ago we became aware that our ... modified to inject Xenopus oocytes. We ... microdispenser to eliminate any tip movement ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Biology Products: